DICE Therapeutics
Rajesh M. has a strong background in clinical operations and program management. Rajesh is currently working at DICE Therapeutics as part of the Clinical Program and Operations team. Prior to that, Rajesh worked at Adanate in a similar role. Rajesh has also gained valuable experience at Genentech, where they spent a decade in the gRED Clinical Operations department. Before joining Genentech, Rajesh worked at Takeda Pharmaceuticals as part of the TGRD Development Operations team. Rajesh began their career at Astellas Pharma, where they served as a Manager of Clinical Studies for six years. Overall, Rajesh M. has over 20 years of experience in the pharmaceutical industry, with a focus on clinical operations and program management.
Rajesh M. has a Master of Business Administration (MBA) degree in Marketing and Finance from the DePaul Driehaus College of Business. Rajesh also holds a Bachelor of Science (BS) degree in Clinical Laboratory Science/Medical Technology/Technologist from the Michigan State University College of Natural Science. Additionally, Rajesh earned a Master of Science (MS) degree in Medical Clinical Sciences/Graduate Medical Studies from the Wayne State University School of Medicine.
DICE Therapeutics
At DICE Therapeutics, we design and develop innovative therapies in immunology for patients with debilitating disease. Seeking to create a future where convenient oral medicines with biologic-like efficacy are available to patients with serious medical conditions, we are developing oral alternatives to medicines currently limited to injectable forms. We believe that such pills will be widely appreciated by patients and doctors alike, as they provide a lower bar to entry than biologics, and as oral medicines can easily be co-formulated with other efficacious drugs. The combination of our core technology with additional, unique biophysical insights has enabled DICE to target protein-protein interactions with small molecules. In doing so, DICE has cracked open a previously intractable set of clinically validated therapeutic targets, including Interleukin-17 (IL-17). Our lead program – an orally bioavailable IL-17 antagonist for the treatment of psoriasis – is currently progressing through IND-enabling studies. In parallel, we continue to advance both partnered and internal pipeline drug discovery programs, providing a robust pre-clinical pipeline.